| 摘要 |
There is described the use of the Human herpesvirus type 6 (HHV-6) U94 gene and its product, the protein Rep, expression vectors and pharmaceutical compositions suitable for the delivery of the U94 gene or the protein encoded therefrom to the therapeutic sites, to inhibit angiogenic and lymphangiogenic processes in a subject in need thereof. |
